CERN Accélérateur de science

Accueil > CERN Experiments > MEDICIS Internal Notes

MEDICIS Internal Notes

Chercher dans 42 notices:
Conseils de recherche
Recherche avancée
Add to Search +
Derniers ajouts:
2024-12-09
10:57
Investigating the potential of Ac-225 labelled pharmaceuticals for Targeted Alpha Therapy: Pre-clinical & Clinical Evaluation / shabana, saed (Pakistan Institute of Engineering & Applied Sciences) ; khan, qaiser (PINSTECH)
Alpha emitters are increasingly recognized as promising candidates for the treatment of inoperable and drug-resistant tumors, owing to their high linear energy transfer (LET) of approximately 100 keV/μm and their short range of 50–100 μm, which corresponds to a few cell diameters. Among these alpha emitters, Actinium-225 (Ac-225) is considered a particularly favorable isotope for targeted alpha therapy due to its longer half-life and its ability to emit four alpha particles in its decay chain. [...]
MED-042.- Geneva : CERN, 2024 - 2. Fulltext: PDF;

Notice détaillée - Notices similaires
2024-12-08
16:53
Detection of 225Ac produced in high-energy photo-spallation of 232Th / Lorusso, Giuseppe (National Physical Laboratory (GB)) ; Ivanov, Peter (NPL) ; Shearman, Robert (NPL)
This proposal is a crucial part of the broader effort to investigate isotope production using laser wake field accelerators (LWFAs). With this technique, a very short duration and powerful laser pulse is focussed through a gas jet or gas cell [...]
MED-041.- Geneva : CERN, 2024 - 2. Fulltext: DOC;

Notice détaillée - Notices similaires
2024-12-08
16:35
Decay data for Ac-226 / Collins, Sean Michael (National Physical Laboratory (GB))
Targeted alpha-particle therapies (TAT) for cancer treatment is an area of significant research and development due to its promise for high efficacy and increased survival, due to its localized energy deposition. Actinium-225 is showing great potential for therapeutic use with many pre-clinical studies underway and significant investment across the globe for its production. [...]
MED-040.- Geneva : CERN, 2024 - 2. Fulltext: DOCX;

Notice détaillée - Notices similaires
2024-07-01
07:55
Tb and Sc radionuclide separation and purification methods from solid targets and liquids for theranostic radiopharmaceutical development / Pajuste, Elina (University of Latvia (LV)) ; Mamis, Edgars (University of Latvia (LV)) ; Kalnina, Patricija (University of Latvia (LV))
There is a new radiochemistry lab being set up at the University of Latvia, dedicated to radionuclide studies with a particular interest in medical radionuclides. While the first studies with Sc isotopes are ongoing, the aim of the lab is to build competence also in radiolanthanides and alpha decay medical radionuclide purification and labeling studies. [...]
MED-039.- Geneva : CERN, 2024 - 2. Fulltext: DOCX;

Notice détaillée - Notices similaires
2024-06-30
12:54
Pre-clinical proof-of-concept of a novel CCR5-targeted radioligand cancer therapy strategy / Garibotto, Valentina (HUG) ; Bejuy, O (HUG) ; Grotzky, Andrea (HUG) ; Montukur, G (UNIGE) ; Bois, Frederic (HUG) ; Hartley, O (UNIGE)
Triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC) are highly prevalent life- threatening diseases for which available treatment options are limited. Theranostic drugs use a ligand of a tumor cell molecular target in combination with different radiometals to both image and therapeutically target a tumor. [...]
MED-038.- Geneva : CERN, 2024 - 2. Fulltext: DOCX;

Notice détaillée - Notices similaires
2023-12-03
23:21
AlphaMET (Metrology for Emerging Targeted Alpha Therapies) / Denis-Bacelar, Ana (NPL) ; Koole, Michel (KULeuven) ; Collins, Sean (NPL)
Targeted alpha therapy (TAT) is a rapidly growing cancer treatment modality, whereby alpha-emitting radiopharmaceuticals are combined with a targeting molecule to selectively seek tumours whilst minimising the damage to healthy cells. TAT is showing promising efficacy and increased survival in clinical trials for a variety of cancers; however, several unmet and unique measurement challenges remain a barrier to enable the safe and optimised implementation of emerging TATs. [...]
MED-037.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

Notice détaillée - Notices similaires
2023-12-03
23:13
Clinical and Pre-clinical Evaluation of Theranostic Pair (Terbium-161 and Terbium-155) for Imaging and Radionuclide Targeted Therapy of Tumors / Khan, Qaiser (PINSTECH)
The idea of theranostic approach is rapidly gaining momentum among the academia and practitioners in nuclear medicine community and there is considerable interest to commercially produce these isotopes for clinical applications. The approach combines diagnosis and therapy with suitable radiotracers [...]
MED-036.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

Notice détaillée - Notices similaires
2023-03-21
17:46
153SM-FAPI-46 RADIOLIGAND THERAPY WITH HIGH-MOLAR ACTIVITY 153SM / Prior, John (CHUV) ; Kratochwill, Clemens (Heidelberg University Hospital) ; Ooms, Marteen (SCK CEN) ; Cocolios, Thomas Elias (KU Leuven (BE)) ; Decristoforo, Clemens (INMUL)
New radiobioconjugates targeting fibroblast overexpressed in certain forms of cancers have recently been developed by the dept of nuclear medicine in Heidelberg and have shown important results in a range of different preclinical and clinical investigations. It demonstrates the potential of a new generation of radiopharmaceuticals targeting the Fibroblast Activation Protein (FAP), quinolone-based FAP inhibitors (FAPI) with a DOTA-chelator moiety and have shown potential benefits in both diagnosis and treatment, including patients presenting disseminated metastasis in lungs. [...]
MED-035.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

Notice détaillée - Notices similaires
2023-03-21
17:40
Determination of 227Ac impurity in 225Ac using alpha spectrometry / Cusnir, Ruslan (Centre Hospitalier Universitaire Lausanne CHUV (CH)) ; Bailat, Claude (CHUV) ; Straub, Marietta (Centre Hospitalier Universitaire Lausanne CHUV (CH))
225 Ac (actinium-225, t 1/2 = 9.9 days) is currently in the spotlight owing to its promising radiotherapeutic applications in nuclear medicine. This alpha-emitter can be produced using an accelerator, however this route involves the formation of an undesirable radionuclidic impurity of 227 Ac (actinium-227, t 1/2 = 21.8 years). [...]
MED-034.- Geneva : CERN, 2023 - 2. Fulltext: PDF;

Notice détaillée - Notices similaires
2023-03-17
15:06
Dual Tumor Targeting Based on a pH Sensitive Peptide Platform / Campello, Maria Paula Cabral (C2TN) ; Paulo, Antonio (C2TN) ; Gano, Lurdes (C2TN) ; Fernandes, Celia (C2TN)
Nowadays it is well established that the microenvironment of solid tumors is associated with increased metabolic activity and hypoxia resulting in an elevated extracellular acidity. Acidosis is associated with tumor development both at very early and at advanced stages, being a tumor property that may serve as a general biomarker. [...]
MED-033.- Geneva : CERN, 2023 - 4. Fulltext: DOCX;

Notice détaillée - Notices similaires